Cancer is a leading cause of death worldwide, accounting for about 10 million and 3.2 million deaths in the world and China in 2022, respectively. Despite extensive studies in the past several decades, many fundamental questions in cancer biology remain poorly understood, including transition from pre-malignancy to tumor, clonal evolution & plasticity, intra-tumor heterogeneity, tumor-stroma interaction, mechanisms for metastasis, therapeutic resistance and the immune microenvironment. As such, comprehensive analysis and interpretation of cancer properties require not only precise investigations, but also collaborative efforts worldwide.
The goal of this symposium is to bring together a diverse range of world-leading cancer biologists and physician scientists to discuss the latest developments, cutting-edge and hot issues in the fields. The attendees from all levels of expertise are encouraged to contribute by participating in discussion. We hope that the symposium serves as a platform for interactions, thereby promoting collaborations to solve the most challenging problems in cancer research.
Session I: Cancer immune signaling
Mechanisms underlying responsiveness and resistance to cancer immunotherapy
New strategies for targeted cancer immunotherapy
The past, present and future of a germline variant in IgG1 coding gene IGHG1
Regulation CD8 T cell dynamics and function in cancer
Session II: Cancer metabolism
Disrupted niche function for normal hematopoiesis in AML is restorable with IL-1R antagonist therapy
Metabolic reprogramming and immune evasion in cancer
Exploiting phospholipid remodeling pathways for cancer treatment
Rewired metabolism as a targetable liability of IDH-mutant leukemia
Session III: New technologies and approaches in cancer research
Big data and artificial intelligence: catalysts for innovation in medicine and healthcare
Radiopharmaceuticals and radiotherapy-activated prodrugs
Innovative oncology therapies based on diverse modalities and translational disease insights
Exploration of macrophages as therapeutic targets in cancer treatment
Session IV: Genome maintenance systems in cancer
Cancer-causing pathogens, cell plasticity and upper GI cancers
The formation of DNA replication-coupled chromatin structures
A tango between STING and TRPV2 on the ER: genome protection and immune regulation
10 Xitoutiao, Youanmen Wai, Fengtai District, Beijing 100069, China
010-86738999
cimr@cimrbj.ac.cn
中文
